[12][13] By 2015, Recursion had closed its Series A round of funding and signed a research agreement with Sanofi Genzyme.

[15][16] The company listed on the Nasdaq Stock Exchange on April 20, 2021 under the ticker symbol RXRX.

[17][18] In November 2021, Recursion signed a $12 billion partnership deal with Roche and its subsidiary Genentech to advance therapies in neuroscience among other things.

[19][20][21] In September 2020, Recursion and Bayer announced their strategic collaboration agreement to discover and develop treatments for fibrotic diseases.

[23] In May 2023, Recursion acquired two companies in the AI-enabled drug discovery space, Toronto-headquartered Cyclica and Montreal-based Valence.